Welcome to our dedicated page for China Sxt Pharmaceuticals news (Ticker: SXTC), a resource for investors and traders seeking the latest updates and insights on China Sxt Pharmaceuticals stock.
China SXT Pharmaceuticals reports developments tied to its specialty pharmaceutical business in Traditional Chinese Medicine Pieces, or TCMPs, and TCM Homologous Supplements. Company updates describe Advanced TCMPs, including Directly-Oral TCMP and After-Soaking-Oral TCMP, as well as fine TCMPs, regular TCMPs, product-planning initiatives, and supply-chain technology projects in the traditional Chinese medicine market.
Recurring SXTC news also covers capital and listing matters, including Nasdaq compliance communications, share consolidations, registered direct offerings, and the company’s dual-class share structure. These updates connect the company’s operating focus in China with changes in its publicly traded Class A ordinary shares and related security structure.
China SXT Pharmaceuticals (NASDAQ: SXTC) announced the development of Kuihuapan and Zhudanfen, two new Advanced TCMP products, aimed at enhancing its market presence. The annual output is anticipated to reach 300,000 bottles, generating sales of approximately RMB 5 million by March 31, 2023. The company is also focusing on increasing production capacity for its Luxuejin product, expecting sales of over RMB 3 million for the fiscal year ending March 31, 2022. The development leverages Chinese Pharmacopoeia standards to improve clinical effectiveness while meeting rising market demand.
China SXT Pharmaceuticals, Inc. (SXTC) announced on December 14, 2021, that it received a notification from Nasdaq regarding its ordinary shares' minimum bid price, which has been below $1.00 for 30 consecutive business days. The notification does not impact the current listing but requires the Company to regain compliance by June 13, 2022. SXTC must achieve a closing bid price of at least $1 for 10 consecutive business days to comply. If compliance is not met, the Company may be eligible for an additional 180 days, potentially involving a reverse stock split.
On October 18, 2021, China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) announced it received a new Pharmaceutical Manufacturing Permit from the Jiangsu Province Medical Products Administration. This permit allows the company to expand its production to include lyophilization processing, a technique that enhances product stability and solubility. The company claims it will be the first in China to manufacture Directly-Oral TCMPs under this new permit. The lyophilization process is essential for their product Luxuejing, aimed at treating various health conditions.
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) announced a 1 for 4 reverse share split effective on February 19, 2021. Shareholders will receive one new share for every four shares they hold. Post-split, ordinary shares are expected to trade at about four times their previous price, but the company cautioned that this price may not be sustained. Approximately 62 million ordinary shares will reduce to about 15.5 million following the split. This action aims to manage share price and liquidity.
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) announced it received a 180-day extension from NASDAQ until March 8, 2021, to meet the minimum bid price requirement of $1.00 per share. The extension was granted as the company met other listing requirements, although it still needs to address the bid price issue. The company plans to potentially implement a reverse stock split if necessary. If compliance isn't achieved, delisting could occur, but the stock remains trading on NASDAQ for now. The company focuses on Traditional Chinese Medicine manufacturing and sales.